Yangjun Wu

955 total citations
22 papers, 537 citations indexed

About

Yangjun Wu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Yangjun Wu has authored 22 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Yangjun Wu's work include Cancer-related molecular mechanisms research (12 papers), RNA modifications and cancer (9 papers) and RNA Research and Splicing (5 papers). Yangjun Wu is often cited by papers focused on Cancer-related molecular mechanisms research (12 papers), RNA modifications and cancer (9 papers) and RNA Research and Splicing (5 papers). Yangjun Wu collaborates with scholars based in China, United States and Italy. Yangjun Wu's co-authors include Shenglin Huang, Lin Huan, Linhui Liang, Xianghuo He, Linguo Xu, Ye Xu, Tianan Guo, Yuqiang Zhou, Shengli Li and Lu Wang and has published in prestigious journals such as Nature Communications, Hepatology and Cancer Research.

In The Last Decade

Yangjun Wu

20 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yangjun Wu China 11 430 384 46 44 42 22 537
Shi Huirong China 10 468 1.1× 426 1.1× 48 1.0× 37 0.8× 31 0.7× 32 593
Shusen Zheng China 10 342 0.8× 321 0.8× 56 1.2× 33 0.8× 32 0.8× 21 444
Brian J. Reon United States 9 505 1.2× 372 1.0× 115 2.5× 59 1.3× 48 1.1× 11 627
Zhixiang Jian China 11 472 1.1× 409 1.1× 69 1.5× 33 0.8× 44 1.0× 18 551
Liming Zhang China 8 319 0.7× 289 0.8× 63 1.4× 25 0.6× 63 1.5× 16 410
Sariat Ibrahim United States 6 492 1.1× 451 1.2× 33 0.7× 46 1.0× 38 0.9× 8 557

Countries citing papers authored by Yangjun Wu

Since Specialization
Citations

This map shows the geographic impact of Yangjun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yangjun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yangjun Wu more than expected).

Fields of papers citing papers by Yangjun Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yangjun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yangjun Wu. The network helps show where Yangjun Wu may publish in the future.

Co-authorship network of co-authors of Yangjun Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yangjun Wu. A scholar is included among the top collaborators of Yangjun Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yangjun Wu. Yangjun Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Yangjun, Yu Zeng, Yong Wu, et al.. (2025). HIF‐1α‐induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP‐ribosylation. Clinical and Translational Medicine. 15(3). e70244–e70244. 1 indexed citations
2.
Wu, Yangjun, et al.. (2025). Bridging the Gap between Transformer-Based Neural Networks and Tensor Networks for Quantum Chemistry. Journal of Chemical Theory and Computation. 21(7). 3426–3439. 2 indexed citations
3.
Wu, Yangjun, Jiajia Wang, Jingjing Zhao, et al.. (2024). LTR retrotransposon-derived LncRNA LINC01446 promotes hepatocellular carcinoma progression and angiogenesis by regulating the SRPK2/SRSF1/VEGF axis. Cancer Letters. 598. 217088–217088. 4 indexed citations
4.
Liu, Chaohua, Fei Xu, Lihua Chen, et al.. (2024). PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer. Molecular Cancer. 23(1). 111–111. 7 indexed citations
5.
Lu, Yicheng, Zhenzhen Duan, Jingni Wu, et al.. (2023). Nanopore long-read RNA sequencing reveals functional alternative splicing variants in human vascular smooth muscle cells. Communications Biology. 6(1). 1104–1104. 8 indexed citations
6.
Wu, Yangjun, Miao Xu, Zheng Feng, et al.. (2023). AUF1-induced circular RNA hsa_circ_0010467 promotes platinum resistance of ovarian cancer through miR-637/LIF/STAT3 axis. Cellular and Molecular Life Sciences. 80(9). 256–256. 17 indexed citations
7.
Wu, Yangjun, et al.. (2023). A Real Neural Network State for Quantum Chemistry. Mathematics. 11(6). 1417–1417. 10 indexed citations
8.
Wu, Yangjun, et al.. (2023). TLM: Token-Level Masking for Transformers.
9.
Hu, Wei, Yangjun Wu, Qili Shi, et al.. (2022). Systematic characterization of cancer transcriptome at transcript resolution. Nature Communications. 13(1). 6803–6803. 11 indexed citations
10.
Liu, Teng, Jingni Wu, Yangjun Wu, et al.. (2022). LncPep: A Resource of Translational Evidences for lncRNAs. Frontiers in Cell and Developmental Biology. 10. 20 indexed citations
11.
Wu, Jingni, et al.. (2021). Maximizing the Utility of Transcriptomics Data in Inflammatory Skin Diseases. Frontiers in Immunology. 12. 761890–761890. 15 indexed citations
12.
Liang, Linhui, Lin Huan, Jiajia Wang, et al.. (2021). LncRNA RP11-295G20.2 regulates hepatocellular carcinoma cell growth and autophagy by targeting PTEN to lysosomal degradation. Cell Discovery. 7(1). 118–118. 22 indexed citations
13.
Qi, Simin, Wei Hu, Dehua Yu, et al.. (2021). Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Molecular Therapy — Nucleic Acids. 26. 11–21. 4 indexed citations
14.
Xu, Linguo, Lin Huan, Tianan Guo, et al.. (2020). LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α. Oncogene. 39(46). 7005–7018. 69 indexed citations
15.
Huan, Lin, Tianan Guo, Yangjun Wu, et al.. (2020). Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response. Molecular Cancer. 19(1). 11–11. 123 indexed citations
16.
17.
Zhou, Yuqiang, Lin Huan, Yangjun Wu, et al.. (2019). LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Letters. 469. 399–409. 60 indexed citations
18.
Wu, Yangjun, Yuqiang Zhou, Lin Huan, et al.. (2019). LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR‐10a‐5p/NCOR2 axis in hepatocellular carcinoma cells. Cancer Science. 110(3). 973–984. 66 indexed citations
19.
Wu, Yangjun, Yiming Zhao, Lin Huan, et al.. (2019). An LTR Retrotransposon-Derived Long Noncoding RNA lncMER52A Promotes Hepatocellular Carcinoma Progression by Binding p120-Catenin. Cancer Research. 80(5). 976–987. 46 indexed citations
20.
Wu, Yangjun, et al.. (1991). [Modelling and kinetic analysis on changrolin block of cardiac Na+ channels].. PubMed. 12(4). 363–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shi Huirong Breakdown of academic impact, for papers by Shusen Zheng Breakdown of academic impact, for papers by Brian J. Reon Breakdown of academic impact, for papers by Zhixiang Jian Breakdown of academic impact, for papers by Liming Zhang Breakdown of academic impact, for papers by Sariat Ibrahim
Rankless by CCL
2026